

From: [REDACTED] [mailto:[REDACTED]@pfizer.com]

Sent: 20 July 2010 12:00

To: TA Comm B

Subject: FW: NICE MTA - Gastro-intestinal stromal tumours (unresectable/metastatic) - imatinib (review) - ACD for consultation

Dear Jeremy

Thank you for the opportunity to comment on the appraisal consultation document for Imatinib for the treatment of unresectable and/or metastatic gastrointestinal stromal tumours.

We have no substantive challenges with respect to the content of the document. Pfizer oncology recognises the complexities associated with assessing the cost-effectiveness of treatments for people with rarer cancers. Because of this we believe that there is a strong case for greater pragmatism in evaluating these medicines.

If you require any further information, please let me know

Kind regards

[REDACTED]

[REDACTED] | [REDACTED] | Tel: [REDACTED] | Fax: [REDACTED] | [REDACTED]@pfizer.com | Pfizer Ltd, Walton Oaks,
Dorking Road, Walton-on-the-Hill, Tadworth, Surrey KT20 7NS

Working together for a healthier world™